AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04478110 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education Session on General Health
Description: Participants in the control group received a group education session in a similar format with that of the intervention group delivered by trained Korean community health educators. Different from the intervention group, the education focused on general health education and primary prevention issues, including routine health examinations and screening for various diseases such as cancer. Korean version of work and communication with a physician, and arranging transportation. standard printed materials and guidelines related to the education contents were also provided, including CRC screening guidelines.
Study NCT04415619 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Xenograft bone substitute (Osteo-biol)
Description: Xenograft bone substitute will be placed over the implant to cover the bone defect after extraction.
Study NCT01620697 — intervention group
Intervention type: PROCEDURE
Intervention: Colorectal surgery
Description: Colorectal surgery
Study NCT01630798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GI heptapeptide
Description: Investigational Agent Name: GI heptapeptide, Linear, 7 amino acid peptide sequence ASYNYDA with a 5-FITC tag and NH2 terminus. Investigational Agent Administration (see SOP in Appendix C) ASYNYDA-GGGSK-(5-FITC)-NH2 0.8 mg lyophilized powder per single-use amber vial Lyophilized powder reconstituted with 5 ml of 0.9% NaCl Final 100 µM concentration for single, one-time topical application Entire 5 ml volume (100 uM concentration) will be sprayed topically onto esophagus by the nurse/physician during the procedure through a standard endoscopy spray catheter (Olympus Medical, Tokyo Japan, PW-5V-1)
Study NCT02559557 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Participate in focus groups
Study NCT02559557 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Undergo Spanish-adapted skills training and homework assignments
Study NCT02559557 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Answer questionnaires
Study NCT02559557 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Answer questionnaires
Study NCT02571972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dorzolamide-timolol
Description: On enrollment, eligible patients will be started on topical dorzolamide-timolol in the study eye twice daily for the study duration
Study NCT01193894 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fresubin
Description: Medical food (food for special medical purposes)
Study NCT01888744 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GnRH agonist
Study NCT01888744 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GnRH antagonist
Study NCT04537754 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: bleaching device
Description: activated bleaching
Study NCT04568811 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adenovirus Type-5 Vectored COVID-19 Vaccine
Description: Low dose adenovirus type-5 vectored COVID-19 vaccine (5E10 vp)
Study NCT01223768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetyl-l-Carnitine
Description: 2g per day
Study NCT01223768 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: twice per day
Study NCT03947255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brentuximab vedotin
Description: 1.8 mg/kg given intravenously (IV)
Study NCT01933204 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture is a collection of procedures involving penetration of the skin with needles to stimulate certain points on the body. In its classical form it is a characteristic component of traditional Chinese medicine (TCM), a form of alternative medicine, and one of the oldest healing practices in the world.
Study NCT01933204 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Climen 21 Tablets
Description: Climen Tablets are commonly used for menopausal symptoms
Study NCT02699853 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02699853 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical Cystectomy
Description: Undergo RRC
Study NCT02699853 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical Cystectomy
Description: Undergo ORC
Study NCT00961662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-Tagatose
Description: powder to be dissolved in water prior to dosage.
Study NCT00961662 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: D-Tagatose
Description: powder to be dissolved in water prior to dosage.
Study NCT00556621 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: cisplatin
Study NCT00556621 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: gemcitabine hydrochloride
Study NCT00556621 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: biopsy
Study NCT00556621 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: cystoscopy
Study NCT00556621 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: therapeutic conventional surgery
Study NCT00556621 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: radiation therapy
Study NCT01818986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sipuleucel-T
Study NCT00869635 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy
Description: PDT with Photofrin® 2mg/kg i.v. 48hrs before laser activation
Study NCT05080101 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Therapy Program
Description: Patients in control group (n=14) will receive 40-mins conventional physiotherapy session for 3-days per week, over 6 weeks. Conventional physiotherapy will consist of stretching and strengthening exercises, postural alignment exercises, as well as electrotherapy such as transcutaneous electric magnetic stimulation (TENS) which will be applied to lumbar region with a frequency of 100 Hz, 50-100 μsec current duration for 20 minutes, hotpack which will be applied to lumbar region for 20 mins, and ultrasound application which will be applied to the lumbar region with a Chattanooga Intelect Mobile device at a frequency of 1 MHz, at a dose of 1.5 W/cm2, for 6 minutes using a 10 cm2 head.
Study NCT05080101 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Basic Body Awareness Therapy Group Program
Description: Patients in study group (n=14) will receive Basic Body Awareness Therapy (BBAT) 3 days in a week, over 6 weeks in addition to conventional physiotherapy. BBAT will consist of flexibility exercises and various cognitive exercises in supine, position, sitting position and standing position. These exercises will be consist of exercises such as body scanning, breathing, sound resonance.
Study NCT02490267 — intervention group
Intervention type: OTHER
Intervention: Quality of Life questionnaire
Study NCT04373044 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Given PO
Study NCT04373044 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hydroxychloroquine
Description: Given PO
Study NCT04373044 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Given PO
Study NCT04373044 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Administration
Description: Given Po
Study NCT02116426 — intervention group
Intervention type: BIOLOGICAL
Intervention: Blood work in the ambulance
Description: Blood sample for copeptin and troponin HS testing is taken during ambulance care.
Study NCT02116426 — intervention group
Intervention type: BIOLOGICAL
Intervention: Blood work upon arrival in the emergency room
Description: Blood in drawn for copeptin and troponin HS testing upon arrival in the emergency room.
Study NCT02116426 — intervention group
Intervention type: BIOLOGICAL
Intervention: Blood work at 3 hours post-arrival in the emergency room
Description: Blood is drawn for troponin HS testing 3 hours after the patient's arrival in the emergency room.
Study NCT02037035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Study NCT00869635 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Photodynamic therapy
Description: PDT with Photofrin® 2mg/kg i.v. 48hrs before laser activation
Study NCT00869635 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Photodynamic therapy
Description: PDT with Photofrin® 2mg/kg i.v. 48hrs before laser activation
Study NCT00869635 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Systemic chemotherapy except S-1
Description: Variable systemic chemotherapy except S-1
Study NCT01349205 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine and sodium Benzoate 10 mg/kg IV
Description: IV, 10mg/kg, IVP, 1 time
Study NCT01349205 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine and Sodium Benzoate 20 mg/kg IV
Description: IV, 20 mg/kg, IVP, 1 time
Study NCT01349205 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9 NS Saline
Description: IV, 0-10 ml, IVP, 1 time
Study NCT02444507 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nexium powder for injection and infusion 40 mg
Description: Reference Drug, Active substance: Esomeprazole 40 mg, Each single dose of esomeprazole 40 mg will be administrated as intravenous infusion over 30 minutes.
Study NCT02444507 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomelone Powder for Solution for Injection / Infusion 40 mg
Description: Test Drug, Active substance: Esomeprazole 40 mg, Each single dose of esomeprazole 40 mg will be administrated as intravenous infusion over 30 minutes.
Study NCT04096950 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MT-3921 Low dose
Description: MT-3921 Low dose, intravenous, single dosing
Study NCT04968626 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PI-LL
Description: The pelvic parameters were collected including PI, pelvic tilt (PT), sacral slope (SS) and LL ,and compared between IS patients and the AS group. Besides, spinopelvic malalignment was defined as an absolute value of PI-LL greater than 10.In the IS group,the clinical symptoms were assessed with the Japanese Orthopaedic Association (JOA) score and the visual analogue scale (VAS). We compared spinopelvic parameters between the asymptomatic adults and the IS patients. Additionally, we investigated correlations between spinopelvic parameters and clinical symptoms.
Study NCT01990976 — intervention group
Intervention type: DEVICE
Intervention: MRI
Description: In Paris centre, a total body NMR imaging will be done with standard T2- and T1-weighted images.
Study NCT01990976 — intervention group
Intervention type: PROCEDURE
Intervention: Biopsy
Description: biopsy of the vastus lateralis muscle
Study NCT05072054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin Oral Tablet
Description: Atorvastatin 40 mg
Study NCT05072054 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin Oral Tablet
Description: Rosuvastatin 20 mg
Study NCT01692743 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home Monitoring
Description: Participants log onto the TELE-IBD website weekly to answer questions about disease symptoms, adherence, side effects, to check body weight and to receive educational content. Participants receive self action plans after each self-testing session. Alerts are generated to the nurse coordinator if certain clinical criteria are met.
Study NCT01692743 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home Monitoring
Description: Participants log onto the TELE-IBD website every other week to answer questions about disease symptoms, adherence, side effects, to check body weight and to receive educational content. Participants receive self action plans after each self-testing session. Alerts are generated to the nurse coordinator if certain clinical criteria are met.
Study NCT02049346 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epoetin alpha or beta (Epoetin group)
Description: Erythropoetin doses in that were adjusted according to the approved prescribing information, without additional restrictions.~Doses of erythropoetin were decreased by 25% for Hb values >12 and ≤13 g/dL and increased by 25% for Hb \<11 and ≥10 g/dL. erythropoetin doses were increased by 50% for Hb \<10 g/dL. Treatment was interrupted temporarily if Hb exceeds 13 g/dL.~The doses for all patients were adjusted so that haemoglobin concentrations were maintained within a target range of 11-12 g/dL during the study.
Study NCT02049346 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darbepoetin alfa
Description: Subjects in that group received Darbepoetin alfa once every week or every 2 weeks as per protocol. Doses of Darbepoetin alfa were decreased by 25% for Hb values >12 and ≤13 g/dL and increased by 25% for Hb \<11 and ≥10 g/dL. Darbepoetin alfa doses and increased by 50% for Hb \<10 g/dL. Treatment was interrupted temporarily if Hb exceeds 13 g/dL.~The doses were adjusted so that haemoglobin concentrations were remain within a target range of 11-12 g/dL during the study.~If a dose of Epoetin alpha/ beta does not equate exactly to a unit dose of Darbepoetin alfa at switching, then the nearest available unit dose of Darbepoetin alfa was used.
Study NCT02049346 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methoxy polyethylene glycol-epoetin beta
Description: Patients in that arm received Intravenous MIRCERA monthly. The initial dose was 120 mcg, 200 mcg or 360 mcg, for patients had previously received a weekly dose of Epoetin alpha/ beta of less than 8000 IU, between 8000 to16 000 IU or more than16000IU respectively. MIRCERA doses were adjusted according to the approved prescribing information, without additional restrictions.~Doses of MIRCERA were decreased by 25% for Hb values >12 and ≤13 g/dL and increased by 25% for Hb \<11 and ≥10 g/dL. MIRCERA doses were increased by 50% for Hb \<10 g/dL. Treatment was interrupted temporarily if Hb exceeds 13 g/dL.~The doses of MIRCERA were adjusted so that haemoglobin concentrations were maintained within a target range of 11-12 g/dL during the study.
Study NCT01881009 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hybrid Closed-loop System
Description: Medtronic Revel insulin pump, Enlite 3 sensor, Minimed transmitter, PID-IFB (proportional-integral-derivative based with insulin feedback) algorithm on an Android platform with remote monitoring.
Study NCT01818986 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Ablative Body Radiation
Study NCT01888744 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hP-hMG
Study NCT01888744 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human chorionic gonadotropin
Description: induction of final oocyte maturation
Study NCT01888744 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone
Study NCT01881009 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sensor-augmented pump
Description: Medtronic Revel insulin pump, Enlite 3 sensor, Minimed transmitter.
Study NCT00353301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib hydrochloride
Description: Patients will receive single-agent Tarceva, 150 mg/day
Study NCT00715884 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CYPHER® ELITE™ Sirolimus-Eluting Stent System
Description: Drug eluting stent
Study NCT00353301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Patients will receive a loading dose of 6 mg of Rapamune seven days after beginning treatment with Tarceva™ followed by a dose of 2mg/day.
Study NCT01132846 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will be randomized to receive Low dose Dopamine or placebo plus optimal diuretic or Low dose Nesiritide or placebo plus optimal diuretic.
Study NCT01132846 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nesiritide
Description: Active Comparator: Low Dose Nesiritide~Participants randomized to the low dose nesiritide arm will receive nesiritide of 0.005 ug/kg/min or placebo during the first 72 hours in the trial.
Study NCT00715884 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CYPHER® Bx VELOCITY® Sirolimus-eluting Stent System
Description: Drug eluting stent
Study NCT02918591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozine
Description: All 6type 2 diabetic participant will receive treatment with Empagliflozine during 2 month
Study NCT01132846 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dopamine
Description: Participants randomized to the low dose dopamine arm will receive dopamine of 2ug/kg/min or placebo during the first 72 hours in the trial.
Study NCT04471376 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sugammadex
Description: Sugammadex group received a rocuronium infusion producing blockade by qualitative train-of-four ≥2 at the ulnar nerve. 2 mg/kg of Sugammadex will be infused when conducting TcMEP
Study NCT04351932 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: bone marrow mesenchymal stem cells
Description: intrarticular bone marrow mesenchymal stem cells injection
Study NCT04351932 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Adipose Mesenchymal stem cells
Description: intrarticular adipose mesenchymal stem cells injection
Study NCT03375138 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: belatacept
Description: Specified dose on specified days
Study NCT02313415 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: UC-MSCs therapy
Description: Before considering whether patients meet the inclusion criteria, they are diagnosed as intrauterine adhesions with at least one unsuccessful hysteroscopic surgery. And after that there will be history taking, physical examination, ultrasound examination and hysteroscopy examination. If they agree to participate, they will receive separation of adhesions by hysteroscopy surgery and endometrial biopsies, then a collagen scaffold loaded with UC-MSCs will be transplanted into the uterine cavity. The procedure was performed after taking 6 mg/day × 10 days Progynova, continuous administration of the same dosage Progynova for 30 days and 60mg of progesterone were injected on the 30th day post-operation. Postoperative observation including ultrasound examination once a month for 3 times and hysteroscopy after 3 months. The doctor will select an appropriate time for pregnancy and follow-up including requiring patients to do some unscheduled visits.
Study NCT01015820 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EGD with EUS
Description: EUS was performed in order to measure blood flow in duodenum.
Study NCT01015820 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: EGD with EUS
Description: EUS was performed in order to measure blood flow in duodenum.
Study NCT01015820 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 4D-ELF
Description: During the EUS, blood flow was measured in the duodenum with the 4D-ELF device.
Study NCT01015820 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: 4D-ELF
Description: During the EUS, blood flow was measured in the duodenum with the 4D-ELF device.
Study NCT02910219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crofelemer
Description: Crofelemer 125 mg BID during cycles 1-2 of THP or TCHP
Study NCT01347632 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Metronidazole
Description: All participants had BV at baseline. They all received metronidazole 500 mg po BID for 7 days
Study NCT05599113 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extracorporeal Shock Wave Therapy
Description: Extracorporeal shock wave therapy (ESWT) is an expedient remedy that is used in various joint and non-invasive muscle pain treatments
Study NCT04101669 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RESET Liner
Description: The RESET System is provided as a single-use, sterile device and consists of an RESET Liner preloaded, packaged and sterilized within the RESET Delivery System. The RESET Delivery System is utilized to deliver the RESET Liner to the proximal small intestine. The RESET Liner is removed using the RESET Retrieval System. The RESET System incorporates no pharmacological, biological tissue or blood products.
Study NCT04101669 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Patient receives upper endoscopy but no treatment
Study NCT02077504 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MEG and MRI
Description: CONDUCTOME
Study NCT01170312 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Autologous conditioned plasma (ACP)
Description: ACP is not a drug as the patient's own blood plasma is re-injected into the surgical site.
Study NCT04130438 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nebivolol
Description: The intervention to be tested is oral beta blocker (nebivolol 2.5 mg) vs. calcium channel blocker (Diltiazem-SR 120 mg) vs. placebo. Once enrolled, baseline data will be gathered and subjects will be randomly assigned to a treatment arm. Subjects will be instructed to take their assigned study drug once a day for 30 days.